LLY

1,070.14

+0.01%↑

JNJ

205.37

-1.16%↓

ABBV

228.73

+0.59%↑

UNH

324.38

+0.04%↑

AZN

91.96

+0.51%↑

LLY

1,070.14

+0.01%↑

JNJ

205.37

-1.16%↓

ABBV

228.73

+0.59%↑

UNH

324.38

+0.04%↑

AZN

91.96

+0.51%↑

LLY

1,070.14

+0.01%↑

JNJ

205.37

-1.16%↓

ABBV

228.73

+0.59%↑

UNH

324.38

+0.04%↑

AZN

91.96

+0.51%↑

LLY

1,070.14

+0.01%↑

JNJ

205.37

-1.16%↓

ABBV

228.73

+0.59%↑

UNH

324.38

+0.04%↑

AZN

91.96

+0.51%↑

LLY

1,070.14

+0.01%↑

JNJ

205.37

-1.16%↓

ABBV

228.73

+0.59%↑

UNH

324.38

+0.04%↑

AZN

91.96

+0.51%↑

Search

Revvity Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

97.76 0.13

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

96.66

Max

98.16

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-8.6M

47M

Pardavimai

-21M

699M

P/E

Sektoriaus vid.

51.072

76.798

Pelnas, tenkantis vienai akcijai

1.18

Dividendų pajamingumas

0.28

Pelno marža

6.675

Darbuotojai

11,000

EBITDA

-14M

181M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+13.76% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

0.28%

2.37%

Kita Ex Dividend data

2026-01-16

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

223M

12B

Ankstesnė atidarymo kaina

97.63

Ankstesnė uždarymo kaina

97.76

Naujienos nuotaikos

By Acuity

19%

81%

32 / 374 reitingas Healthcare

Revvity Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-22 23:54; UTC

Pagrindinės rinkos jėgos

Novo Nordisk ADRs Gain on FDA Approval of First GLP-1 in Pill Form

2025-12-22 19:08; UTC

Įsigijimai, susijungimai, perėmimai

Correction to Alphabet to Buy Intersect Article

2025-12-22 17:21; UTC

Įsigijimai, susijungimai, perėmimai

Alphabet to Buy Intersect for $4.75 Billion as AI-Investment Plans Grow -- Update

2025-12-22 16:46; UTC

Įsigijimai, susijungimai, perėmimai

Alphabet to Buy Intersect for $4.75 Billion in Cash

2025-12-22 23:50; UTC

Rinkos pokalbiai

Nikkei May Decline as Yen Rebounds -- Market Talk

2025-12-22 23:42; UTC

Rinkos pokalbiai

Gold Hits Record High Amid Rising Geopolitical Risks -- Market Talk

2025-12-22 22:31; UTC

Uždarbis

Zhejiang Sanhua Intelligent Controls: Higher Demand for Air-Conditioning Components Supported Results >002050.SZ

2025-12-22 22:31; UTC

Uždarbis

Zhejiang Sanhua Intelligent Controls: Higher Demand for Refrigeration Supported Results >002050.SZ

2025-12-22 22:30; UTC

Uždarbis

Zhejiang Sanhua Intelligent Controls Sees 2025 Net CNY3.87B, Up 25% on Year >002050.SZ

2025-12-22 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-22 21:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2025-12-22 21:37; UTC

Įsigijimai, susijungimai, perėmimai

Capricorn: Project Is Contiguous to Capricorn's Golden Range, Fields Find Tenure

2025-12-22 21:36; UTC

Įsigijimai, susijungimai, perėmimai

Capricorn to Pay A$500,000 Cash, A$4M in New Shares

2025-12-22 21:35; UTC

Įsigijimai, susijungimai, perėmimai

Capricorn to Acquire Prospective Package From Tempest Minerals

2025-12-22 21:35; UTC

Įsigijimai, susijungimai, perėmimai

Capricorn Metals to Buy Yalgoo Project Tenement Package for A$4.5M

2025-12-22 20:54; UTC

Įsigijimai, susijungimai, perėmimai

Middle West Partners Buys Paul Stuart From Mitsui & Co.

2025-12-22 20:52; UTC

Įsigijimai, susijungimai, perėmimai

HCL Technologies: HCLSoftware to Acquire Jaspersoft From Cloud Software Group >532281.BY

2025-12-22 20:09; UTC

Rinkos pokalbiai

U.S. Natural Gas Settles Lower in Choppy Trade -- Market Talk

2025-12-22 19:56; UTC

Rinkos pokalbiai

Crude Gains as U.S. Increases Actions Against Venezuela -- Market Talk

2025-12-22 19:49; UTC

Įsigijimai, susijungimai, perėmimai

A Topsy-Turvy Year for Oracle and the Ellisons Will Bleed into 2026 -- Barrons.com

2025-12-22 19:23; UTC

Rinkos pokalbiai

Mexico's Inflation Seen Easing in Early December -- Market Talk

2025-12-22 19:23; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-12-22 19:02; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2025-12-22 19:02; UTC

Rinkos pokalbiai

Precious Metals Climb to New Heights -- Market Talk

2025-12-22 18:45; UTC

Rinkos pokalbiai

Canadian Trade-Exposed Industries At Forefront of Job Weakness -- Market Talk

2025-12-22 18:30; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Intersect Selling Portion of Assets as Part of Alphabet Deal -- Market Talk

2025-12-22 18:23; UTC

Įsigijimai, susijungimai, perėmimai

What Yogi Berra Would Say About the Talks to Take Over Warner Bros. Discovery -- Barrons.com

2025-12-22 17:20; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2025-12-22 17:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-12-22 17:06; UTC

Įsigijimai, susijungimai, perėmimai

Alphabet to Buy Intersect for $4.75B as AI-Investment Plans Grow -- Update

Akcijų palyginimas

Kainos pokytis

Revvity Inc Prognozė

Kainos tikslas

By TipRanks

13.76% į viršų

12 mėnesių prognozė

Vidutinis 111.22 USD  13.76%

Aukščiausias 123 USD

Žemiausias 100 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Revvity Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

10 ratings

5

Pirkti

5

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

32 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Revvity Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat